RESUMEN
PURPOSE: Despite potential clinical benefits, implementation of pharmacogenomics (PGx) faces many technical and clinical challenges. These challenges can be overcome with a comprehensive and systematic implementation model. METHODS: The development and implementation of PGx were organized into eight interdependent components addressing resources, governance, clinical practice, education, testing, knowledge translation, clinical decision support (CDS), and maintenance. Several aspects of implementation were assessed, including adherence to the model, production of PGx-CDS interventions, and access to educational resources. RESULTS: Between August 2012 and June 2015, 21 specific drug-gene interactions were reviewed and 18 of them were implemented in the electronic medical record as PGx-CDS interventions. There was complete adherence to the model with variable production time (98-392 days) and delay time (0-148 days). The implementation impacted approximately 1,247 unique providers and 3,788 unique patients. A total of 11 educational resources complementary to the drug-gene interactions and 5 modules specific for pharmacists were developed and implemented. CONCLUSION: A comprehensive operational model can support PGx implementation in routine prescribing. Institutions can use this model as a roadmap to support similar efforts. However, we also identified challenges that will require major multidisciplinary and multi-institutional efforts to make PGx a universal reality.Genet Med 19 4, 421-429.
Asunto(s)
Prestación Integrada de Atención de Salud/métodos , Sistemas de Atención de Punto , Sistemas de Apoyo a Decisiones Clínicas , Registros Electrónicos de Salud , Humanos , Modelos Teóricos , Farmacogenética/educación , Medicina de PrecisiónRESUMEN
Activation of the Janus kinase family/signal transducer and activator of transcription (JAK/STAT) signaling pathway has been associated with the pathogenesis and progression of both solid and hematologic malignancies. We have detected constitutive activation of STAT5 in malignant B cells derived from patients with Waldenström's macroglobulinemia (WM). Although short hairpin RNA-mediated knockdown of the STAT5A and STAT5B isoforms did not affect cellular proliferation, loss of STAT5 significantly decreased immunoglobulin M (IgM) secretion. A similar dose-dependent inhibition of IgM secretion was observed when WM cell lines were treated with a small molecule inhibitor of STAT5. These data suggest that STAT5 is involved in regulating IgM production in WM and that inhibition of STAT5 may represent a novel therapeutic strategy for lowering IgM levels in WM patients.
Asunto(s)
Inmunoglobulina M/metabolismo , Factor de Transcripción STAT5/genética , Proteínas Supresoras de Tumor/genética , Macroglobulinemia de Waldenström/genética , Células Cultivadas , Regulación de la Expresión Génica/efectos de los fármacos , Técnicas de Silenciamiento del Gen , Células HEK293 , Humanos , ARN Interferente Pequeño/farmacología , Factor de Transcripción STAT5/metabolismo , Vías Secretoras/efectos de los fármacos , Vías Secretoras/genética , Activación Transcripcional/efectos de los fármacos , Activación Transcripcional/fisiología , Proteínas Supresoras de Tumor/metabolismo , Macroglobulinemia de Waldenström/inmunología , Macroglobulinemia de Waldenström/metabolismoRESUMEN
Cytokines within the tumor microenvironment play an important role in supporting the growth and survival of B-cell malignancies. One such cytokine, IL-21, promotes the growth of myeloma and Hodgkin lymphoma cells while inducing apoptosis in chronic lymphocytic leukemia. However, the biologic significance of IL-21 has not been examined in Waldenstrom macroglobulinemia (WM), a B-cell lymphoma characterized by elevated serum IgM and a lymphoplasmacytic bone marrow infiltrate. We report here on the presence of IL-21 in the bone marrow of patients with WM and have identified activated T cells as the source of this cytokine. We readily detected the IL-21 receptor on malignant WM B cells and show that IL-21 significantly increases both IgM secretion and cellular proliferation of these cells with no effect on viability. IL-21 rapidly induces phosphorylation of STAT3 in WM cells, and treatment of the WM cell line MWCL-1 with a STAT3 inhibitor abolished the IL-21-mediated increases in cellular proliferation and IgM secretion. IL-21 also increased the expression of known STAT3 targets involved in B-cell differentiation, including BLIMP-1, XBP-1, IL-6, and IL-10. Overall, our data indicate that IL-21 in the bone marrow microenvironment significantly affects the biology of WM tumor cells through a STAT3-dependent mechanism.
Asunto(s)
Proliferación Celular , Inmunoglobulina M/biosíntesis , Interleucinas/metabolismo , Microambiente Tumoral/inmunología , Macroglobulinemia de Waldenström/metabolismo , Macroglobulinemia de Waldenström/patología , Médula Ósea/inmunología , Médula Ósea/metabolismo , Línea Celular Tumoral , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Humanos , Immunoblotting , Inmunoglobulina M/inmunología , Inmunohistoquímica , Interleucinas/inmunología , Activación de Linfocitos/inmunología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal/inmunología , Linfocitos T/inmunología , Linfocitos T/metabolismo , Macroglobulinemia de Waldenström/inmunologíaRESUMEN
BACKGROUND: In a phase 3 study of adults with active lupus nephritis, addition of voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids led to significant improvements in the proportion of participants achieving complete and partial renal response as well as sustained reduction in proteinuria. This analysis examined the efficacy and safety of voclosporin in a subgroup of the phase 3 study with proliferative lupus nephritis and high levels of proteinuria. METHODS: Participants were randomized to oral voclosporin (23.7 mg twice daily) or placebo for 12 months; all participants received MMF and low-dose glucocorticoids. This analysis includes participants with class III or IV (±class V) lupus nephritis and baseline urine protein-creatinine ratio (UPCR) ≥3 g/g. Efficacy end points included complete renal response (UPCR ≤0.5 g/g with stable eGFR, low-dose glucocorticoids, and no rescue medication), partial renal response (≥50% reduction from baseline UPCR), and UPCR over time. Safety outcomes were also assessed. RESULTS: A total of 148 participants were in the voclosporin ( n =76) and control ( n =72) arms. At 12 months, 34% and 11% of participants in the voclosporin and control arms, respectively, achieved a complete renal response (odds ratio, 4.43; 95% confidence interval [CI], 1.78 to >9.99; P = 0.001). A partial renal response was achieved by 65% of the voclosporin arm and 51% of the control arm at 12 months (odds ratio, 1.60; 95% CI, 0.8 to 3.20; P = 0.18). More voclosporin- than control-treated participants achieved UPCR ≤0.5 g/g (51% versus 26%), and voclosporin-treated participants met this end point significantly earlier (hazard ratio, 2.07; 95% CI, 1.19 to 3.60; P = 0.01). The incidence of adverse events was similar between the arms; mean eGFR values remained stable and within normal range in both arms. CONCLUSIONS: Addition of voclosporin to MMF and low-dose glucocorticoids resulted in a significantly higher proportion of participants with proliferative lupus nephritis achieving complete and partial renal responses as well as earlier reductions in proteinuria, with no evidence of worsening kidney function.
Asunto(s)
Nefritis Lúpica , Adulto , Humanos , Nefritis Lúpica/tratamiento farmacológico , Nefritis Lúpica/complicaciones , Inmunosupresores/efectos adversos , Ciclosporina/efectos adversos , Ácido Micofenólico/efectos adversos , Proteinuria/tratamiento farmacológico , Proteinuria/etiología , Glucocorticoides/efectos adversos , Resultado del TratamientoRESUMEN
Although proinflammatory and chemotactic cytokines can profoundly affect the tumor microenvironment, and many of them have been shown to have therapeutic efficacy in preclinical models, the role of these molecules in Waldenström macroglobulinemia (WM) remains poorly understood. In this study, simultaneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cytokines including CCL5, G-CSF, and soluble IL-2 receptor, that were significantly elevated in WM patients whereas IL-8 and EGF levels were significantly lower in these patients compared with healthy controls. Interestingly, CCL5 levels positively correlated with features of disease aggressiveness such as elevated IgM levels and bone marrow involvement. Functional analysis of tumor microenvironment revealed a functional correlation between CCL5 levels and IL-6 levels, a proinflammatory cytokine with an important role in normal and malignant B-cell biology. Furthermore, CCL5 stimulated IL-6 secretion in WM stromal cells resulting in increased IgM secretion by WM malignant cells via the JAK/STAT signaling pathway. Thus, together these results define a novel signaling network in the WM tumor microenvironment controlling IgM secretion and suggest CCL5 as a potential target for the treatment of this disease.
Asunto(s)
Quimiocina CCL5/inmunología , Interleucina-6/inmunología , Transducción de Señal/inmunología , Células del Estroma/inmunología , Microambiente Tumoral/inmunología , Macroglobulinemia de Waldenström/inmunología , Biopsia , Médula Ósea/inmunología , Médula Ósea/metabolismo , División Celular/inmunología , Línea Celular Tumoral , Movimiento Celular/inmunología , Supervivencia Celular/inmunología , Quimiocina CCL5/sangre , Humanos , Inmunoglobulina M/inmunología , Interleucina-6/metabolismo , Receptores de Quimiocina/inmunología , Receptores de Quimiocina/metabolismo , Índice de Severidad de la Enfermedad , Células del Estroma/citología , Células del Estroma/metabolismo , Macroglobulinemia de Waldenström/patología , Macroglobulinemia de Waldenström/terapiaRESUMEN
Waldenström macroglobulinemia (WM) is a rare, lymphoplasmacytic lymphoma characterized by hypersecretion of immunoglobulin M (IgM) protein and tumor infiltration into the bone marrow and lymphatic tissue. Our understanding of the mechanisms driving the development and progression of WM is currently by the shortage of representative cell models available for study. We describe here the establishment of a new WM cell line, MWCL-1. Comprehensive genetic analyses have unequivocally confirmed a clonal relationship between this novel cell line and the founding tumor. MWCL-1 cells exhibit an immunophenotype consistent with a diverse, tumor clone composed of both small B lymphocytes and larger lymphoplasmacytic cells and plasma cells: CD3â», CD19âº, CD20âº, CD27âº, CD38âº, CD49Dâº, CD138âº, cIgMâº, and κâº. Cytogenetic studies identified a monoallelic deletion of 17p13 (TP53) in both the cell line and the primary tumor. Direct DNA resequencing of the remaining copy of TP53 revealed a missense mutation at exon 5 (V143A, GTG>GCG). In accordance with primary WM tumors, MWCL-1 cells retain the ability to secrete high amounts of IgM protein in the absence of an external stimulus. The genetic, immunophenotypic, and biologic data presented here confirm the validity of the MWCL-1 cell line as a representative model of WM.
Asunto(s)
Línea Celular Tumoral/fisiología , Línea Celular Tumoral/ultraestructura , Macroglobulinemia de Waldenström/genética , Macroglobulinemia de Waldenström/patología , Anciano , Hibridación Genómica Comparativa , Dermatoglifia del ADN , Técnica del Anticuerpo Fluorescente , Humanos , Inmunofenotipificación , Hibridación Fluorescente in Situ , MasculinoRESUMEN
Waldenström's macroglobulinemia is a B-cell malignancy characterized by a lymphoplasmacytic infiltration into the bone marrow and a monoclonal immunoglobulin M (IgM) protein in the serum. It remains incurable despite advances in current therapy, and the decision to treat patients as well as the choice of treatment administered can be rather complex. Management of this disease should utilize a risk-adapted approach. Patients with smoldering or asymptomatic Waldenström's macroglobulinemia with preserved hematological function should be observed without initial therapy. Symptomatic patients with modest hematological compromise, IgM-related neuropathy requiring therapy or hemolytic anemia unresponsive to corticosteroids should receive standard doses of rituximab alone without maintenance therapy. Patients who have significant constitutional symptoms, profound hematological compromise, symptomatic bulky disease or hyperviscosity should be treated with combination therapy. Any patient with symptoms of hyperviscosity should be treated with plasmapheresis. For patients who relapse after an initial response to therapy of greater than two years in duration, the original therapy should be repeated. For patients who had an inadequate response to initial therapy or a response of less than two years duration, an alternative agent or combination should still be used. An autologous stem cell transplant should be considered in all eligible patients with relapsed disease.
Asunto(s)
Macroglobulinemia de Waldenström/terapia , Terapia Combinada , Humanos , Recurrencia , Macroglobulinemia de Waldenström/diagnóstico , Macroglobulinemia de Waldenström/tratamiento farmacológicoRESUMEN
OBJECTIVE: Chemoradiation is the mainstay of therapy for advanced cervical cancer, with the most effective treatment regimens involving combinations of radiosensitizing agents. However, administration of radiosensitizing chemotherapeutics concurrently with pelvic radiation is not without side effects. The aim of this study was to examine the utility of localized drug delivery as a means of improving drug targeting of radiosensitizing chemotherapeutics to the cervix while limiting systemic toxicities. METHODS: An initial proof-of-concept study was performed in 14 healthy women following local administration of diazepam utilizing a novel cervical delivery device (CerviPrep™). Uterine vein and peripheral blood samples were collected and diazepam was measured using a GC-MS method. In the follow-up study, gemcitabine was applied to the cervix in 17 women undergoing hysterectomy for various gynecological malignancies. Cervical tissue, uterine vein blood samples, and peripheral plasma were collected, and gemcitabine and its deaminated metabolite 2',2'-difluorodeoxyuridine (dFdU) were measured using HPLC-UV and LC/MS methods. RESULTS: Targeted delivery of diazepam to the cervix was consistent with parent drug detectable in the uterine vein of 13 of 14 women. In the second study, pharmacologically relevant concentrations of gemcitabine (0.01-6.6 nmol/g tissue) were detected in the cervical tissue of 11 of 16 available specimens with dFdU measureable in 15 samples (0.04-8.8 nmol/g tissue). Neither gemcitabine nor its metabolites were detected in the peripheral plasma of any subject. CONCLUSIONS: Localized drug delivery to the cervix is possible and may be useful in limiting toxicity associated with intravenous administration of chemotherapeutics for radiosensitization.
Asunto(s)
Cuello del Útero/efectos de los fármacos , Cuello del Útero/metabolismo , Desoxicitidina/análogos & derivados , Diazepam/administración & dosificación , Neoplasias de los Genitales Femeninos/tratamiento farmacológico , Neoplasias de los Genitales Femeninos/cirugía , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/sangre , Antimetabolitos Antineoplásicos/farmacocinética , Cuello del Útero/cirugía , Desoxicitidina/administración & dosificación , Desoxicitidina/sangre , Desoxicitidina/farmacocinética , Diazepam/sangre , Diazepam/farmacocinética , Sistemas de Liberación de Medicamentos , Interacciones Farmacológicas , Femenino , Neoplasias de los Genitales Femeninos/metabolismo , Humanos , Fármacos Sensibilizantes a Radiaciones/administración & dosificación , Fármacos Sensibilizantes a Radiaciones/farmacocinética , GemcitabinaRESUMEN
Gemcitabine (dFdC) is a chemotherapeutic nucleoside analog that undergoes uptake via equilibrative nucleoside transporters (hENT) followed by sequential phosphorylation to the active triphosphate moiety (dFdCTP). Its deaminated metabolite, 2',2'-difluorodeoxyuridine (dFdU), competes with the parent compound for cellular entry via hENTs, but over time dFdU increases the net intracellular accumulation of dFdC by a currently unknown mechanism. In this study, we investigated whether dFdU affects intracellular phosphorylation of gemcitabine by modulating the activity of deoxycytidine kinase (dCK). We report here that coincubation of dFdU with dFdC significantly increases intracellular levels of dFdCTP. dFdCTP was not identified as a substrate for hENTs, suggesting that dFdU affects the formation rather than elimination of the triphosphate. To further characterize the disposition of dFdC in the presence of dFdU, the net intracellular radioactivity of [5-(3)H]dFdC and corresponding metabolic profile were evaluated in HeLa cells transfected with dCK-targeting small interfering RNA. Intracellular radioactivity significantly decreased in cells with compromised intracellular phosphorylation, which was mainly due to a loss in dFdCTP. Although dFdU increased the net intracellular radioactivity of [5-(3)H]dFdC at 24 h in control cells, this increase was abolished in the absence of dCK activity, strongly suggesting that the interaction between dFdU and dFdC occurs via modulation of both transport and metabolism. In conclusion, we have demonstrated that the intracellular distribution of dFdC is dependent on both transport and metabolic processes, and that by affecting the rate at which dFdC enters the cell, the presence of dFdU may be altering the metabolic fate of the parent compound (dFdC).
Asunto(s)
Desoxicitidina Quinasa/metabolismo , Desoxicitidina/análogos & derivados , Floxuridina/análogos & derivados , Antineoplásicos/metabolismo , Antineoplásicos/farmacocinética , Transporte Biológico , Desaminación , Desoxicitidina/metabolismo , Desoxicitidina/farmacocinética , Floxuridina/metabolismo , Floxuridina/farmacocinética , Células HeLa , Humanos , Inactivación Metabólica , Fosforilación , Polifosfatos/metabolismo , ARN Interferente Pequeño/genética , Células Tumorales Cultivadas , GemcitabinaRESUMEN
The disposition of many medications is altered during pregnancy. Due to changes in many physiological parameters as well as variability in the activity of maternal drug-metabolizing enzymes, the efficacy and toxicity of drugs used by pregnant women can be difficult to predict. Enzymatic activity exhibited by the placenta and fetus may affect maternal drug distribution and clearance also. In addition, efflux transporters have been detected in high amounts within placental tissue, potentially limiting fetal exposure to xenobiotics. Dosage adjustments of antiepileptic drugs, antidepressants and anti-infectives administered during pregnancy have been required due to these changes in drug metabolism and disposition. As such, pregnant women may require different dosing regimens than both men and non-pregnant women.
Asunto(s)
Quimioterapia , Preparaciones Farmacéuticas/metabolismo , Embarazo/metabolismo , Adulto , Animales , Proteínas Portadoras/metabolismo , Femenino , Feto/metabolismo , Humanos , Farmacocinética , Placenta/metabolismo , Embarazo/fisiologíaRESUMEN
B-cell activating factor-receptor (BAFF-R) is the primary BAFF receptor that is responsible for promoting B-cell development and survival. Malignant B-cells exploit the BAFF/BAFF-R system, and high serum BAFF levels or genetic alterations in BAFF receptors have been found in B-cell cancers. BAFF signaling impacts pro-survival pathways. However, other than nuclear factor-κB2 (NF-κB2), little is known about the specific pathways activated by individual BAFF receptors. Using a novel BAFF-R expression model we have demonstrated that activation of BAFF-R, independent of transmembrane activator and cytophilin ligand interactor (TACI) and B-cell maturation antigen (BCMA), can induce phosphorylation of Akt and glycogen synthase kinase 3ß (GSK3ß). Expression of an activated form of BAFF-R also enhanced a pro-survival gene expression pattern, including the novel BAFF-regulated gene Pin1, whose expression was phosphatidyl inositol 3-kinase (PI3K)-dependent. Additionally, we showed that TRAF6 is essential for mediating BAFF-R dependent activation of Akt. Together these data describe a novel role for TRAF6 in BAFF-R-specific activation of the PI3K pathway and provide evidence suggesting a new role for Pin1 in BAFF-R signaling.
Asunto(s)
Linfoma de Células B/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Receptores de Interleucina-4/metabolismo , Transducción de Señal , Factor 6 Asociado a Receptor de TNF/metabolismo , Factor Activador de Células B/farmacología , Línea Celular Tumoral , Activación Enzimática , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Glucógeno Sintasa Quinasa 3/metabolismo , Glucógeno Sintasa Quinasa 3 beta , Humanos , Linfoma de Células B/genética , Proteínas Proto-Oncogénicas c-akt/metabolismo , Receptores de Interleucina-4/genéticaRESUMEN
While the effect of TGF-ß on malignant B cells in non-Hodgkin lymphoma (NHL) has been previously evaluated, studies to specifically define the role of TGF-ß in tumor immunity in B-cell NHL are limited. We found that soluble TGF-ß, secreted by both lymphoma cells and intratumoral T cells, is present in the serum of patients with B-cell NHL. Soluble TGF-ß promoted regulatory T (T(reg)) cells by enhancing expression of Foxp3 in CD4(+) T cells and suppressed effector helper T (T(H)) cells by inhibiting expression of IFN-γ and IL-17. Blockade of the IL-2 signaling pathway diminished the effect of soluble TGF-ß on T cell differentiation. Furthermore, we found that membrane-bound TGF-ß is expressed specifically on the surface of malignant B cells in B-cell NHL. TGF-ß was able to bind to the surface of lymphoma B cells through an interaction with heparan sulfate (HS) but not through the TGF-ß receptor. We showed that pretreatment of lymphoma B cells with TGF-ß significantly inhibits the proliferation and cytokine production of intratumoral T cells. Taken together, these results suggest that tumor-associated soluble and membrane-bound TGF-ß are involved in the regulation of intratumoral T cell differentiation and function in B-cell NHL.
Asunto(s)
Linfocitos B/citología , Diferenciación Celular , Membrana Celular/metabolismo , Linfoma no Hodgkin/patología , Linfocitos T/citología , Factor de Crecimiento Transformador beta/química , Factor de Crecimiento Transformador beta/metabolismo , Linfocitos B/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/inmunología , Humanos , Interleucina-2/biosíntesis , Linfoma no Hodgkin/inmunología , Linfoma no Hodgkin/metabolismo , Transducción de Señal/efectos de los fármacos , Transducción de Señal/inmunología , Solubilidad , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Linfocitos T/metabolismo , Factor de Crecimiento Transformador beta/farmacología , Microambiente Tumoral/efectos de los fármacos , Microambiente Tumoral/inmunologíaRESUMEN
PURPOSE: Although the International Prognostic Score (IPS) is the gold standard for risk-stratifying patients with classical Hodgkin lymphoma (cHL), these criteria do not accurately predict outcome. As cytokines are critically involved in driving cHL, we tested whether pretreatment serum cytokine levels could provide additional prognostic information. EXPERIMENTAL DESIGN: Thirty cytokines were measured in pretreatment serum from 140 patients with cHL and compared with 50 nonlymphoma controls. Patients were followed for event-free survival (EFS) and overall survival (OS), and Cox proportional hazards regression models were used to assess the association of individual cytokines and the cytokine profiles with outcome via unadjusted and IPS-adjusted HR. RESULTS: Twelve cytokines (EGF, bFGF, G-CSF, HGF, IL-6, IL-8, IL-12, IL-2R, IP-10, MIG, TNF-α, and VEGF) were significantly (P < 0.05) higher in patients with cHL than controls; elevated levels of HGF, IL-6, IL-2R, IP-10, and MIG were all associated with poorer EFS. Only interleukin-2 receptor (IL-2R; P = 0.002) and interleukin (IL)-6 (P < 0.001) were independently prognostic. Patients with increased IL-6 and IL-2R had a significantly higher risk of early relapse and death, a finding that remained significant even after IPS-based risk stratification. Although elevated IL-6 and IL-2R correlated with the IPS, soluble CD30 (sCD30), and thymus and activation-related chemokine (TARC) levels, the two-cytokine model remained independently predictive of prognosis. CONCLUSIONS: Elevated pretreatment serum cytokines are associated with increased disease relapse and inferior survival in cHL. Thus, the pretreatment cytokine profile, particularly serum levels of IL-6 and IL-2R, may be used to identify patients with cHL at high risk for early-disease relapse.
Asunto(s)
Enfermedad de Hodgkin/sangre , Interleucina-6/sangre , Recurrencia Local de Neoplasia/sangre , Receptores de Interleucina-2/sangre , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Supervivencia sin Enfermedad , Femenino , Regulación Neoplásica de la Expresión Génica/genética , Enfermedad de Hodgkin/patología , Enfermedad de Hodgkin/terapia , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/terapia , Estadificación de Neoplasias , Pronóstico , Modelos de Riesgos ProporcionalesRESUMEN
While high serum concentrations of immunoglobulin M (IgM) protein are responsible for much of the morbidity associated with Waldenström's macroglobulinemia (WM), the mechanisms controlling IgM secretion in this malignancy remain unknown. The Jak/Stat signaling pathway mediates the effects of most cytokines involved in stimulating immunoglobulin production in nonmalignant B cells. However, in many hematopoietic malignancies, cytokine-driven stimulation of the Jak/Stat pathway is hyperactive, promoting the expression of genes associated with proliferation and survival. Autocrine/paracrine signaling of cytokines present in the tumor microenvironment may lead to persistent Jak/Stat signal transduction in WM as well. Yet despite evidence implicating the Jak/Stat pathway in the pathogenesis of WM, the relationship between Jak/Stat-mediated cytokine signaling and IgM hypersecretion has not been defined. Through the use of targeted Jak/Stat inhibitors, it is now possible to examine the contribution of aberrant cytokine signaling to IgM production, potentially allowing for a more targeted approach to WM therapy.